Beyond CSF: Quanterix’s Simoa Platform Brings Blood-Based Biomarkers to the Forefront

Published Date: 09 Apr 2025

Mark Roskey, PhD, chief scientific officer at Quanterix, provided clinical insight on the function of the company’s Simoa technology and the incorporation of various biomarkers to aid in the diagnosis of Alzheimer disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.

2.

Even a few mutated cells can significantly impact how blood cancers develop, study finds

3.

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

4.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

5.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot